Back to search

Article

The Effect of Cardiometabolic Drugs on Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

2024-12-30

Abstract excerpt

The link between cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD)/metabolic dysfunction-associated fatty liver disease (MAFLD)/metabolic dys-function-associated steatotic liver disease (MASLD) is well-established at both epidemi-ological and pathophysiological level. Among the common pathophysiological mechanisms involved in the development and progression of both diseases, oxidative stre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
aea80831-da1f-545e-8a52-cea6eaf9dd2b
DOI
10.20944/preprints202412.2468.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Effect of Cardiometabolic Drugs on Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)DOI 10.20944/preprints202412.2468.v1
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and BeyondSemantic proximity
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.Semantic proximity
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver DiseaseSemantic proximity
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease.Semantic proximity
Non-alcoholic fatty liver disease: what the clinician needs to know.Semantic proximity
Non-alcoholic Fatty Liver Disease (NAFLD) Management in the CommunitySemantic proximity
Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future PerspectivesSemantic proximity
Common Pathogenetic Pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes MellitusSemantic proximity
Recent advances in understanding and managing non-alcoholic fatty liver diseaseSemantic proximity
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.Semantic proximity
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity
Non-alcoholic fatty liver disease pathogenesis: the present and the future.Semantic proximity
Select a neighboring publication to make it the new centre.